Steven Bloch, MD
General Partner, Canaan Partners
A former entrepreneur and practicing physician, Steve knows firsthand the challenges of building successful healthcare companies. Unfazed by the complexity in healthcare, whether regulatory, scientific or technical, Steve’s mission at Canaan is to find companies that make healthcare delivery more efficient. In fact, he’s determined to make the entire medical experience better: more empathetic, more transparent, more affordable… maybe even pleasant. We’re all for it. Besides, he brings in a great bedside manner and loves coming to work each day, so it’s a win-win for everyone.
As an early investor and chairman, Steve helped Advanced BioHealing (ABH), a leader in regenerative medicine, grow from a seed stage company to a $750M all-cash acquisition by Shire, generating a 15X return for Canaan. He currently serves on the boards of companies in Healthcare IT (Truveris and Ambra Health); BioPharma (Envisia and Liquidia); MedTech (MitraSpan and Onkos Surgical); and Diagnostics (Sample6).
Before joining Canaan in 2002, Steve founded multiple start-ups, including Radiology Management Sciences (RMS), a pioneer in managing radiology benefits for health plans, where he was CEO for 6 years. Steve also helped start OmniSonics Medical Technologies, which engineered novel ultrasonic catheters for treating vascular occlusive disease, and he co-founded TeleRad, an early teleradiology services company. Prior to embarking on startups, Steve was a strategic consultant for the Arthur D. Little firm. Steve was a Ewing Marion Kauffman Fellow, an educational program to develop future leaders in venture capital.
Steve obtained his AB from Dartmouth College, received his MA in the history of science and public policy from Harvard, and he earned his medical degree from the University of Rochester. Steve received his medical training at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine). It was there that he contracted the entrepreneurial bug – the one thing he admits he can’t cure.